NCT02572388View on ClinicalTrials.gov

A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 15, 2015

Primary Completion Date

August 29, 2017

Study Completion Date

August 29, 2017

Conditions
Malaria
Interventions
BIOLOGICAL

R21

BIOLOGICAL

Matrix-M1

Trial Locations (2)

OX3 7LE

Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford

W12 0HS

NIHR Wellcome Trust Clinical Research Facility, Hammersmith Hospital, London

All Listed Sponsors
lead

University of Oxford

OTHER

NCT02572388 - A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1 | Biotech Hunter | Biotech Hunter